share_log

微創醫療：股份發行人截至二零二三年十二月三十一日的證券變動月報表

MICROPORT: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

香港交易所 ·  Jan 5 03:36
Summary by Moomoo AI
微創醫療科學有限公司於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本維持不變，為5,000,000,000股普通股，每股面值0.00001美元，總額50,000美元。在股份期權方面，根據購股權計劃，公司註銷了19,187股份期權，使得本月底結存的股份期權數目為87,128,441股。此外，另一購股權計劃亦註銷了744,388股份期權，本月底結存為73,281,577股。公司還有一個股份計劃，上月底結存的股份期權數目為19,156,102股，本月無變動。在可換股票據方面，公司購回了部分2026年到期零息可換股債券，減少了217,000,000美元，餘額為448,000,000美元。同時，公司亦發行了新的2028年到期5.75%可換股債券，總額為220,000,000美元。報告最後確認，所有證券的發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的要求。
微創醫療科學有限公司於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本維持不變，為5,000,000,000股普通股，每股面值0.00001美元，總額50,000美元。在股份期權方面，根據購股權計劃，公司註銷了19,187股份期權，使得本月底結存的股份期權數目為87,128,441股。此外，另一購股權計劃亦註銷了744,388股份期權，本月底結存為73,281,577股。公司還有一個股份計劃，上月底結存的股份期權數目為19,156,102股，本月無變動。在可換股票據方面，公司購回了部分2026年到期零息可換股債券，減少了217,000,000美元，餘額為448,000,000美元。同時，公司亦發行了新的2028年到期5.75%可換股債券，總額為220,000,000美元。報告最後確認，所有證券的發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的要求。
Micro-Chung Medical Sciences Limited filed with Hong Kong Trading and Settlement Limited on 5 January 2024 with Hong Kong Trading and Settlement Holdings Limited the Monthly Securities Change Report for the year ended 31 December 2023. The report showed that the company's regulated/registered share capital remained unchanged at 5,000,000,000 shares of ordinary shares with a face value of $0.00001 per share for a total of $50,000. In terms of stock options, under the Share Option Plan, the Company has written off 19,187 share options, bringing the number of stock options outstanding at the end of the month to 87,128,441 shares. In addition, another share option plan cancelled 744,388 share options, with 73,281,577 shares outstanding at the end of the month. The company also has a share plan with...Show More
Micro-Chung Medical Sciences Limited filed with Hong Kong Trading and Settlement Limited on 5 January 2024 with Hong Kong Trading and Settlement Holdings Limited the Monthly Securities Change Report for the year ended 31 December 2023. The report showed that the company's regulated/registered share capital remained unchanged at 5,000,000,000 shares of ordinary shares with a face value of $0.00001 per share for a total of $50,000. In terms of stock options, under the Share Option Plan, the Company has written off 19,187 share options, bringing the number of stock options outstanding at the end of the month to 87,128,441 shares. In addition, another share option plan cancelled 744,388 share options, with 73,281,577 shares outstanding at the end of the month. The company also has a share plan with 19,156,102 shares outstanding at the end of last month, unchanged this month. IN TERMS OF CONVERTIBLE STOCK NOTES, THE COMPANY REPURCHASED A PORTION OF THE ZERO-DIVIDEND CONVERTIBLE NOTES DUE 2026, REDUCING $217,000,000 WITH A BALANCE OF $448,000,000. At the same time, the Company also issued new 5.75% Convertible Notes due 2028, totaling $220,000,000. The report finally confirms that all issuance of securities has been approved by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more